Mary Wilson
Well-known member
Last Updated: February 3, 2021
National Institutes of Health
Background
Tocilizumab is a recombinant humanized anti-interleukin (IL)-6 receptor monoclonal antibody that is approved by the Food and Drug Administration (FDA) for the treatment of certain rheumatologic disorders and cytokine release syndrome induced by chimeric antigen receptor T cell (CAR-T) therapy. Similar agents in this class include sarilumab, which is FDA-approved for the treatment of rheumatoid arthritis. It is hypothesized that modulating the levels of pro-inflammatory IL-6 or its effects may improve the course of COVID-19. To date, no IL-6 inhibitor is FDA-approved or authorized for the treatment of COVID-19.
https://www.covid19treatmentguidelines.nih.gov/statement-on-tocilizumab/
National Institutes of Health
Background
Tocilizumab is a recombinant humanized anti-interleukin (IL)-6 receptor monoclonal antibody that is approved by the Food and Drug Administration (FDA) for the treatment of certain rheumatologic disorders and cytokine release syndrome induced by chimeric antigen receptor T cell (CAR-T) therapy. Similar agents in this class include sarilumab, which is FDA-approved for the treatment of rheumatoid arthritis. It is hypothesized that modulating the levels of pro-inflammatory IL-6 or its effects may improve the course of COVID-19. To date, no IL-6 inhibitor is FDA-approved or authorized for the treatment of COVID-19.
https://www.covid19treatmentguidelines.nih.gov/statement-on-tocilizumab/
